Pharmaceutical manufacturers of Lisdexamfetamine

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

Veranova boasts over 50 years of expertise and is a frontrunner in the creation and fabrication of intricate and specialized APIs for the pharmaceutical and biotech sectors. It was previously a segment of Johnson Matthey, specializing in intricate and regulated chemical processes. The company delivers customized services throughout all phases of drug development and is split into Generics and Originators. It possesses a variety of development technologies and areas of expertise, along with a cooperative approach to API manufacturing and procedures.

Established in 1973 and based in Mumbai, India, Alkem started its operations as a healthcare marketing firm. Alkem is a major participant in the market for branded and generic drugs in India. The company has a strong presence in various therapeutic segments such as Anti-infective, Gastro-intestinal, Pain Management, Vitamins/Minerals/Nutritions, Central Nervous System, Anti-diabetic, Anti-osteoporosis, Anti-malarial, Cardiovascular, Immunosuppressants, and Nutraceutical segment.

Headquartered in Chandigarh, India, Ind-Swift Laboratories Ltd. today is a global manufacturer of APIs, Intermediates, and formulations (through group collaboration). With regulated 6+ manufacturing sites (including 2 group subsidiaries) in Punjab and Jammu, we cater to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. Today, Ind-Swift Laboratories Ltd. is a significant player in manufacturing APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. We also hold global leadership positions in the Macrolide Antibiotic segment.

Our proprietary products (APIs) cater to the general pharmaceutical sector. We consistently deliver high-quality products and services, utilizing some of the most challenging chemical technologies in the world responsibly and continuously

Established in the year 1991, SM Biomed Sdn. Bhd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates based out in Malaysia With our state-of-the-art manufacturing facility certified by USFDA, EDQM, EUGMP and NPRA (Malaysia), we are dedicated to improve the quality of life through developing and delivering innovative solutions and products at an affordable cost. With a legacy spanning more than three decades and pioneers for Macrolide based antibiotics, we work with customers globally with speed, efficiency and cost effective manufacturing capabilities. SM Biomed has grown as a market leader in Macrolides antibiotics and evolved into a knowledge driven company providing reliable pharmaceutical services including developing and manufacturing APIs and Intermediates. From pipeline to production, we make innovative, quality driven and customised products more accessible. We are a quality driven and R&D focused API manufacturing company with a diverse product portfolio catering various therapeutic segments.

Technology and innovation is the backbone of Embio’s success, which allows us to achieve a leadership position as a manufacturer of Active Pharmaceutical Ingredients (APIs), Intermediates and Speciality chemicals catering to a range of global customers in the pharmaceutical, nutraceutical, food, cosmetic, crop & plant protection segments. With 30+ years of experience in handling bacterial, fungal & Category 1 GMO bio-transformation, Embio has demonstrated an impeccable track record in creating sustainable, environmental friendly and disruptive technologies. With licenses to manufacture Schedule-1 & Schedule-2 substances, Embio is a leading global player in the domain of controlled substances, advanced intermediates & chiral molecules. Embio’s State of the Art manufacturing facility is approved by US-FDA, PMDA, KFDA, COFEPRIS & WHO-GMP. Our products & services cater to the stringent requirements of a large customer base in more than 70 countries, with a major share from regulated markets that includes originator and large multi-national companies.

Chr. Olesen Group operates as a global consortium of partner-led distribution and production firms. Chr. Olesen focuses on distributing ingredients and API’s across four distinct sectors: Feed, Food, Pharma, and Vet Pharma. The manufacturing arm of the group, Chr. Olesen Synthesis, is headquartered in Denmark and specializes in API's and intermediates, with particular emphasis on controlled substances such as Buprenorphine HCL, Buprenorphine base, and Buprenorphine intermediates, along with Dexamphetamine sulphate, Hydromorphone, Terbinafine, and Tolfenamic acid. Established in 1885, Chr. Olesen Group is presently under the management of the fourth generation.